Immunology

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer

Retrieved on: 
Monday, February 19, 2024
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical Trials, Metabolism, Immunotherapy, AstraZeneca, News, Daiichi Sankyo, National Cancer Institute, Lung cancer, Triple-negative breast cancer, Immunology, Patient, Cleavage, Biopharmaceutical, Social media, Progression-free survival, Treatment, BLA, Docetaxel, IHC, DXD, Pharmacotherapy, NSCLC, Breast cancer, Gefitinib, PD-1, Safety, Lung, Pemetrexed, PFS, American Cancer Society, Pircher, Observational study, MD, Sapporo Medical University, Food, Cancer, ADC, OS, Immunoglobulin G, Death, Medicine, Pharmaceutical industry

AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have received prior systemic therapy.

Key Points: 
  • AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have received prior systemic therapy.
  • In patients with nonsquamous NSCLC, datopotamab deruxtecan showed a clinically meaningful PFS benefit and a numerically favorable OS trend.
  • Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “Datopotamab deruxtecan has the potential to offer patients with previously treated advanced nonsquamous non-small cell lung cancer an effective and tolerable alternative to conventional chemotherapy.
  • Additional regulatory submissions for datopotamab deruxtecan in lung and breast cancer are underway globally.

3D Printing Trailblazer ELEGOO Announces Initiative to Boost Women's Roles in STEM

Retrieved on: 
Friday, March 8, 2024
Woman, Doctor of Philosophy, Multimedia, Neuroscience, STEM, Immunology, Neuron, 3D, Growth, Cell, B cell, International Women's Day, Research, Student, 3D printing

Specializing in stem cell disease modeling, Annika innovated a strategy for co-maturing immune cells and neurons from stem cells last year, enabling developmental interaction studies.

Key Points: 
  • Specializing in stem cell disease modeling, Annika innovated a strategy for co-maturing immune cells and neurons from stem cells last year, enabling developmental interaction studies.
  • Throughout her research, Annika Mordelt has found 3D printing technology to be an invaluable tool.
  • Not merely as 2D representations on a screen, but in their full 3D splendor, brought to life by 3D printers," Annika explained.
  • Our goal is to promote gender equality and diversity, inspiring more women to delve into STEM and the exciting realm of 3D printing."

Genezen Announces Strategic Process Development and Manufacturing Partnership Agreement with Seattle Children's Research Institute for X-linked Agammaglobulinemia (XLA) Cell Therapy Program

Retrieved on: 
Wednesday, March 6, 2024
BTK, Division, Seattle Children's, Bone marrow, MD, Infection, CSL, Pediatrics, Hospital, Skin, XLA, Child, Antibody, B cell, University, Immunity, Research institute, Immunotherapy, Immunology, Patient, Immortalised cell line, CGMP, Research, Immune system, Partnership, Vaccine

FISHERS, Ind., March 6, 2024 /PRNewswire/ -- Seattle Children's Research Institute, the research division of Seattle Children's Hospital and renowned global leader in pediatric research, and Genezen, a leading gene and cell therapy contract development and manufacturing organization, have unveiled a strategic manufacturing partnership for Seattle Children's Research Institute's X-linked agammaglobulinemia (XLA) program.

Key Points: 
  • FISHERS, Ind., March 6, 2024 /PRNewswire/ -- Seattle Children's Research Institute, the research division of Seattle Children's Hospital and renowned global leader in pediatric research, and Genezen, a leading gene and cell therapy contract development and manufacturing organization, have unveiled a strategic manufacturing partnership for Seattle Children's Research Institute's X-linked agammaglobulinemia (XLA) program.
  • This collaborative effort is focused on leveraging Genezen's viral vector process development and cGMP manufacturing expertise to advance Seattle Children's XLA gene therapy program.
  • XLA is a rare primary immunodeficiency condition characterized by abnormally low levels of immunoglobulins, also referred to as antibodies.
  • With this program, Seattle Children's is one of our first customers to leverage our Cytegrity™ producer cell line offering from CSL.

Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors

Retrieved on: 
Monday, March 4, 2024
Neoplasm, Biotechnology, Senior, Indiana University, Food, Health, Drug development, Spacecraft, ADC, Stanford University, Doctor of Philosophy, University, Genentech, Safety, Roche, Therapy, Immunology, Food and Drug Administration, Abstract, Patient, Internal medicine, Oncology, Rush Medical College, Vanderbilt University, Publication, Mirati Therapeutics, Cancer, Pharmaceutical industry

"We are thrilled to welcome Julie and Alan as Elevation Oncology's newest directors," said Steve Elms, Chairman of Elevation Oncology.

Key Points: 
  • "We are thrilled to welcome Julie and Alan as Elevation Oncology's newest directors," said Steve Elms, Chairman of Elevation Oncology.
  • On behalf of the Board, I look forward to Julie and Alan's many insights into both clinical and regulatory strategy as Elevation Oncology continues to advance its pipeline of differentiated, potentially best-in-class antibody-drug conjugate (ADC) therapies."
  • Earlier, Dr. Cherrington served as CEO of QUE Oncology, and as President and CEO of Arch Oncology, Revitope Oncology, Inc., Zenith Epigenetics, and Pathway Therapeutics.
  • Dr. Sandler is an accomplished leader in oncology and drug development, with experience leading clinical development and operations, regulatory affairs, drug safety and asset development strategy across industry and academia.

Bexion Pharmaceuticals, Inc. Appoints Dr. Tariq Arshad as Chief Medical Officer

Retrieved on: 
Wednesday, February 28, 2024
Biotechnology, CIPN, MD, ASCO, Strategic planning, SITC, Clinical research, Chemotherapy-induced peripheral neuropathy, AACR, MBA, Society, Immunology, Patient, Immunotherapy, Head, Medical device

COVINGTON, Ky., Feb. 28, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced the appointment of Tariq Arshad, MD, MBA as Chief Medical Officer.

Key Points: 
  • COVINGTON, Ky., Feb. 28, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced the appointment of Tariq Arshad, MD, MBA as Chief Medical Officer.
  • Dr. Arshad is an oncologist with more than 25 years of experience and a successful track record of strategic planning, clinical development, and commercialization.
  • "We are thrilled to appoint Dr. Arshad as Bexion's Chief Medical Officer," said Scott Shively, Bexion's Chief Executive Officer.
  • Dr. Arshad previously led medical strategies for blockbuster biologic therapies approved for clinical use in major immunology indications and other groundbreaking therapies as Head of Medical Affairs for Immunology at Sanofi, and he served as Chief Medical Officer and Head of Clinical Research at Humanigen, developing novel immune-oncology therapies.

Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK

Retrieved on: 
Monday, February 26, 2024
Division, Woman, Autoimmune disease, Assistant, Pain, CD19, Multiple sclerosis, University, Therapy, Rheumatoid arthritis, Immunology, Death, Patient, Autoimmunity, NK, Nature Communications, Infection, University of Pittsburgh, Research, Cancer, Vaccine

WEXFORD, Pa., Feb. 26, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced that it has expanded its exclusive license agreement with the University of Pittsburgh to include autoimmune indications as part of its ongoing development of SNAP-CAR T and SNAP-CAR NK.   This amended agreement builds upon the original exclusive license agreement with the University of Pittsburgh for SNAP-CAR T Cells, a "universal" CAR T technology platform designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, and a recent amendment to the agreement for SNAP-CAR NK, an allogeneic natural killer (NK) cell therapy platform.

Key Points: 
  • WEXFORD, Pa., Feb. 26, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced that it has expanded its exclusive license agreement with the University of Pittsburgh to include autoimmune indications as part of its ongoing development of SNAP-CAR T and SNAP-CAR NK.
  • Autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis, are known to result from autoreactive B cells.
  • "We are again excited to expand our license with Coeptis," said Jason Lohmueller, Ph.D., Assistant Professor of Surgery and Immunology in the Division of Surgical Oncology Research, University of Pittsburgh.
  • According American Autoimmune Related Disease Association , there are more than 100 autoimmune diseases impacting 1 in every 5 Americans, 75% of whom are women.

Groundbreaking! Phase II Data of LP-003 Unveiled by Longbio Pharma at AAAAI2024

Retrieved on: 
Sunday, February 25, 2024
Allergy, Ophthalmology, AAAAI, Omalizumab, Upper respiratory tract infection, Dermatology, Allergic rhinitis, Season, Hematology, Rhinitis, Immunology, Patient, Autoimmunity, Clinical trial, PPP, SOC, Asthma, Insurance, American Academy, Pharmaceutical industry

The presentation of the poster titled "A Phase II study of LP-003, a novel high-affinity, long-acting anti-IgE antibody for allergic rhinitis" by Longbio Pharma marked a significant moment during the conference.

Key Points: 
  • The presentation of the poster titled "A Phase II study of LP-003, a novel high-affinity, long-acting anti-IgE antibody for allergic rhinitis" by Longbio Pharma marked a significant moment during the conference.
  • This Phase II study shows that 100mg LP-003 significantly improved nasal symptoms (TNSS score) of uncontrolled seasonal allergic rhinitis patients despite SoC treatment.
  • We are honored to unveiled the exciting Phase II results of LP-003, the first registrational clinical trial of anti-IgE antibody for AR conducted in China."
  • As Longbio Pharma charts its course forward, the successful Phase II study of LP-003 in allergic rhinitis represents a pivotal milestone in advancing the treatment landscape for allergic diseases.

MEMS in the Global Medical Market: New Report with 2020-2023 Data, CAGR Projections to 2028 and Profiles of Leading Players TE Connectivity, STMicroelectronics, Teledyne Dalsa and Silex Microsystems

Retrieved on: 
Thursday, February 22, 2024
MEMS, Ophthalmology, Regeneration, Drug, DDS, Toxicity, USD, Pressure, Silicon, Intelligence, Permeability, Temperature, Immunology, Cardiology, Honeywell, Growth, Polymer, Teledyne DALSA, ESG, Endocrinology, TE Connectivity, STMicroelectronics, Administration, Glass, Metal, Microelectromechanical systems, Route of administration, Solubility, Proteomics, LOC, Genomics, Diagnosis, Research, Biochemistry

DUBLIN, Feb. 22, 2024 /PRNewswire/ -- The 'Microelectromechanical Systems (MEMS) in Global Medical Markets' report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 22, 2024 /PRNewswire/ -- The 'Microelectromechanical Systems (MEMS) in Global Medical Markets' report has been added to ResearchAndMarkets.com's offering.
  • Of these, microfluidic and LOC devices account for the largest segment of the MEMS device market.
  • In terms of microfluidic devices, the key potential lies in developing cartridges that are highly sensitive, multichannel and multiplexing systems.
  • Competitive intelligence related to leading companies, their global rankings, recent developments, key financials and segmental revenues, and product portfolios
    Profiles of the leading market players, including TE Connectivity, Honeywell International Inc., STMicroelectronics, Teledyne Dalsa, and Silex Microsystems

Real World Evidence Solutions Market Worth $4.5 Billion | MarketsandMarkets™.

Retrieved on: 
Friday, February 16, 2024
Real-World Evidence, Labcorp, Acquisition, Cancer, Syneos Health, SAS Institute, Intelligence, Research, Investment, Real, Immunology, IBM, Drug development, Growth, EHR, Drug discovery, Conditional sentence, Neurology, RWE, Cognizant, Prevalence, Safety, PerkinElmer, IQVIA, Thermo Fisher Scientific, HTA, ChromeOS, Patient, Big data, ICON PLC, Environment, Market development, Partnership, Pharmaceutical industry

Real World Evidence Solutions Market Dynamics:

Key Points: 
  • Real World Evidence Solutions Market Dynamics:
    Key Market Players of Real World Evidence Solutions Industry:
    Prominent players in the Real-World Evidence Solution market include Iqvia Holdings Inc. (US), Merative(US), Optum Inc. (US), Icon Plc.
  • Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the Real-World Evidence Solution market.
  • Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, investments in the Real-World Evidence Solution market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global real-world evidence solution Market.

Real World Evidence Solutions Market Worth $4.5 Billion | MarketsandMarkets™.

Retrieved on: 
Friday, February 16, 2024
Real-World Evidence, Labcorp, Acquisition, Cancer, Syneos Health, SAS Institute, Intelligence, Research, Investment, Real, Immunology, IBM, Drug development, Growth, EHR, Drug discovery, Conditional sentence, Neurology, RWE, Cognizant, Prevalence, Safety, PerkinElmer, IQVIA, Thermo Fisher Scientific, HTA, ChromeOS, Patient, Big data, ICON PLC, Environment, Market development, Partnership, Pharmaceutical industry

Real World Evidence Solutions Market Dynamics:

Key Points: 
  • Real World Evidence Solutions Market Dynamics:
    Key Market Players of Real World Evidence Solutions Industry:
    Prominent players in the Real-World Evidence Solution market include Iqvia Holdings Inc. (US), Merative(US), Optum Inc. (US), Icon Plc.
  • Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the Real-World Evidence Solution market.
  • Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, investments in the Real-World Evidence Solution market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global real-world evidence solution Market.